Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives $9.50 Consensus Price Target from Analysts

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) have been given an average recommendation of “Moderate Buy” by the nine research firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have issued a buy recommendation on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $9.50.

A number of analysts have issued reports on the stock. Wall Street Zen lowered shares of Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Saturday, November 8th. Barclays began coverage on shares of Xeris Biopharma in a report on Monday, December 8th. They set an “overweight” rating and a $9.00 target price on the stock. Zacks Research cut shares of Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xeris Biopharma in a research report on Wednesday, October 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Xeris Biopharma in a report on Friday, November 7th.

Insider Buying and Selling

In other news, Director Barbara-Jean A. Bormann-Kennedy sold 15,000 shares of the business’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $7.09, for a total transaction of $106,350.00. Following the completion of the transaction, the director directly owned 142,500 shares of the company’s stock, valued at approximately $1,010,325. The trade was a 9.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Beth Hecht sold 16,667 shares of the firm’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $7.01, for a total transaction of $116,835.67. Following the completion of the sale, the insider directly owned 1,320,176 shares in the company, valued at approximately $9,254,433.76. This trade represents a 1.25% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 206,976 shares of company stock worth $1,497,495. 6.47% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Xeris Biopharma

Institutional investors and hedge funds have recently modified their holdings of the company. Cetera Investment Advisers lifted its holdings in Xeris Biopharma by 3.9% during the 2nd quarter. Cetera Investment Advisers now owns 46,332 shares of the company’s stock worth $216,000 after buying an additional 1,735 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Xeris Biopharma by 7.6% during the second quarter. China Universal Asset Management Co. Ltd. now owns 32,167 shares of the company’s stock worth $150,000 after purchasing an additional 2,264 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Xeris Biopharma by 7.0% in the second quarter. The Manufacturers Life Insurance Company now owns 54,472 shares of the company’s stock valued at $254,000 after purchasing an additional 3,562 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Xeris Biopharma by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock valued at $461,000 after purchasing an additional 3,594 shares during the last quarter. Finally, Federated Hermes Inc. raised its holdings in Xeris Biopharma by 0.5% during the second quarter. Federated Hermes Inc. now owns 691,381 shares of the company’s stock worth $3,229,000 after purchasing an additional 3,598 shares in the last quarter. Institutional investors and hedge funds own 42.75% of the company’s stock.

Xeris Biopharma Stock Up 2.2%

NASDAQ:XERS opened at $7.37 on Friday. The stock’s fifty day moving average is $7.73 and its two-hundred day moving average is $6.96. Xeris Biopharma has a 52 week low of $3.14 and a 52 week high of $10.08. The stock has a market capitalization of $1.22 billion, a price-to-earnings ratio of -73.69 and a beta of 0.57.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings data on Thursday, November 6th. The company reported $0.00 earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.01). The firm had revenue of $74.38 million during the quarter, compared to analyst estimates of $74.19 million. On average, sell-side analysts expect that Xeris Biopharma will post -0.41 EPS for the current fiscal year.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.